Procedural growth could increase by more than 20% over the next five years,
according to Millennium Research Group
WALTHAM, Mass., May 20 /PRNewswire/ -- According to Millennium Research Group's US Markets for Peripheral Vascular (PV) Devices 2008 report, the thoracic aortic stent graft market is poised to exceed 20% growth over the next five years. Carotid stents are another PV device segment with significant potential, although market expansion in this area is dependent on positive clinical trial data and expanded Centers for Medicare & Medicaid Services (CMS) reimbursement.
Treatment of thoracic aortic disease, a PV condition, is expected to witness a surge over the next five years as manufacturers focus on developing aortic stent grafts specific to this indication. The thoracic aorta is extremely risky to treat surgically because of the high mortality associated with this procedure; thus, the availability of a minimally invasive alternative -- thoracic endovascular aortic repair (TEVAR)-- has garnered a lot of attention among physicians and represents a significant opportunity for market expansion. Next-generation thoracic stent grafts, and clinical trials supporting their efficacy, will expand the treatable patient population, leading to growth in procedures in excess of 20% over the next five years.
Growth in carotid artery stenting procedures slowed to less than 5% per year in 2007 due to a lack of conclusive data supporting the safety and efficacy of the procedure compared to surgical alternatives. Compounding this lack was the CMS decision to not expand reimbursement coverage to include select asymptomatic carotid artery disease patients. In early 2008, CMS decided, however, to reexamine the expansion to reimbursement. If expanded reimbursement is approved, and the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) trial yields favorable results for stenting, carotid stenting growth could jump to greater than 20% before 2012.
"Our market forecasts present variable growth models," says Stephanie LaBelle, Analyst at Millennium Research Group. "These models consider the potential expansion of carotid stenting reimbursement, the completion of CREST, a large randomized clinical study comparing the efficacy of carotid artery stenting versus carotid endarterectomy, and the release of post-market carotid stenting surveillance data. These forecasts are supported by a survey of US physicians who rated expanded CMS reimbursement as the factor that would have the largest impact on growth in carotid stenting procedures; the release of clinical trial data supporting carotid artery stenting was rated second-most important."
The US Markets for Peripheral Vascular Devices 2008 report provides coverage of all key industry competitors, including Abbott Vascular, AngioDynamics, B. Braun, Boston Scientific, Cook Medical, Cordis, C. R. Bard, ev3, Medtronic, W. L. Gore, and Terumo, among others. Global coverage of this report includes Europe, Asia-Pacific, Latin America, Canada, and Japan.
About Millennium Research Group
Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Millennium Research Group
|SOURCE Millennium Research Group|
Copyright©2008 PR Newswire.
All rights reserved